Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Moderna, Inc. Director's Dealing 2025

Feb 28, 2025

30610_dirs_2025-02-28_081960b0-5745-4d8d-bd71-a3f828fa9ec7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2025-02-27

Reporting Person: Klinger Shannon Thyme (Chief Legal Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-02-27 Common Stock M 3094 Acquired 24861 Direct
2025-02-27 Common Stock F 1496 $33.58 Disposed 23365 Direct
2025-02-27 Common Stock M 2653 Acquired 26018 Direct
2025-02-27 Common Stock F 1283 $33.58 Disposed 24735 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-02-27 Restricted Stock Units $ M 3094 Disposed Common Stock (3094) Direct
2025-02-27 Restricted Stock Units $ M 2653 Disposed Common Stock (2653) Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: Includes 342 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on December 13, 2024.

F3: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.

F4: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F5: 25% of the shares subject to this restricted stock unit award vested on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter.